New clinical and real-world data support a subcutaneous treatment pathway from initiation through maintenance treatment, offering dosing convenience for patients and care partners TOKYO and CAMBRIDGE, Mass., July 12, 2026 /PRNewswire/ — Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB)…
Source: prnewswire
Country: United States